David Kirn
Fondatore presso 4D MOLECULAR THERAPEUTICS, INC.
Patrimonio netto: 35 M $ in data 30/06/2024
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Theresa Janke | F | 49 | 11 anni | |
| Fariborz Kamal | M | 61 | 6 anni | |
| Noriyuki Kasahara | M | 62 | 2 anni | |
| Scott Bizily | M | 52 | 3 anni | |
| Charles Theuer | M | 60 |
The University of California, San Francisco
| 12 anni |
| Terry Hermiston | M | - |
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | 5 anni |
| Robert Kim | M | 63 | 4 anni | |
| John Milligan | M | 63 | 4 anni | |
| Jacob Chacko | M | 45 | 5 anni | |
| Shawn Tomasello | F | 65 | 4 anni | |
| Susannah Gray | F | 63 | 4 anni | |
| Nancy Miller-Rich | F | 65 | 4 anni | |
| Ian Gardiner | M | - |
University of Oxford
| - |
| Bernard J. Taylor | M | 67 |
University of Oxford
| - |
| Julian Pei | M | - | - | |
| Ngaire Woods | F | 62 |
University of Oxford
| 14 anni |
| Anil Razdan | M | 75 |
University of Oxford
| - |
| David A. Larson | M | 83 |
The University of California, San Francisco
| 38 anni |
| An Song | M | - | 3 anni | |
| Robin Hanson | M | - |
University of Oxford
| - |
| Stephen Pulman | M | - |
University of Oxford
| - |
| Jan Tadeusz Czernuszka | M | - |
University of Oxford
| - |
| Stefan Karl Neubauer | M | - |
University of Oxford
| - |
| Uneek Mehra | M | 51 | 1 anni | |
| Sheila Barrett | F | - |
University of Oxford
| - |
| David Kerr | M | - |
University of Oxford
| - |
| Lars Henrik Fugger | M | 64 |
University of Oxford
| 17 anni |
| Zhan Feng Cui | M | 62 |
University of Oxford
| - |
| J. Doyne Farmer | M | 72 |
University of Oxford
| - |
| Won Chul Cho | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Jinkyun Kim | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Mankyu Park | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Elish Angiolini | F | - |
University of Oxford
| - |
| Daekyeong Bae | M | - |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | 5 anni |
| Stephen Westaby | M | - |
University of Oxford
| - |
| David J. Teece | M | 75 |
University of California, Berkeley
| 42 anni |
| Jeff Orenstein | M | - |
University of Oxford
| - |
| André S. Hoffmann | M | 66 |
University of Oxford
| - |
| Philip E. Wolfson | M | 79 |
The University of California, San Francisco
| 38 anni |
| Andrew Wolff | M | 69 |
The University of California, San Francisco
| 38 anni |
| Robin Steele | F | 68 |
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | - |
| Len Blavatnik | M | 66 |
University of Oxford
| - |
| William R. Miller | M | 95 |
University of Oxford
| - |
| James Pennington | M | 81 |
The University of California, San Francisco
| 38 anni |
| Ivan M. Lieberburg | M | 74 |
The University of California, San Francisco
| 36 anni |
| Crispin Davis | M | 75 |
University of Oxford
| - |
| William Castell | M | 76 |
University of Oxford
| - |
| Lai Kuen Louey | M | 64 |
University of Oxford
| 13 anni |
| Soo Min Yeoh | F | 68 |
University of Oxford
| - |
| Patrick Pichette | M | 61 |
University of Oxford
| - |
| Lionel Tarassenko | M | 67 |
University of Oxford
| 27 anni |
| Indrajit Wickramasinghe | M | - |
University of Oxford
| - |
| Simon Boddie | M | 64 |
University of Oxford
| 3 anni |
| Julie Baddeley | F | 73 |
University of Oxford
| - |
| Alex Hawker | M | - |
University of Oxford
| - |
| Benjamine Reid | M | - |
University of Oxford
| - |
| Nigel Shadbolt | M | 68 |
University of Oxford
| - |
| Geert Linnebank | M | 68 |
University of Oxford
| - |
| Marc K. Hellerstein | M | 72 |
The University of California, San Francisco
| 37 anni |
| Marc Feldmann | M | 79 |
University of Oxford
| 13 anni |
| Wendy Becker | F | 58 |
University of Oxford
| - |
| John Hagan Pryce Bayley | M | - |
University of Oxford
| 21 anni |
| Peter Ratcliffe | M | 69 |
University of Oxford
| - |
| Geoffrey Hale | M | - |
University of Oxford
| - |
| Cheryl Musch | F | - |
University of Oxford
| - |
| Malcolm McCulloch | M | - |
University of Oxford
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Qing Huang | M | 62 |
University of California, Berkeley
| 6 anni |
| Paul Jacobs | M | 61 |
University of California, Berkeley
| 9 anni |
| Kamal H. Khayat | M | - |
University of California, Berkeley
| 7 anni |
| Carl Perez | M | - |
University of California, Berkeley
| 8 anni |
| David Schaffer | M | 53 | 9 anni | |
| Irving Mintzer | M | - |
University of California, Berkeley
| 13 anni |
| Sung Su Han | M | 72 |
University of California, Berkeley
| 12 anni |
| Ze Xiang Li | M | 63 |
University of California, Berkeley
| 4 anni |
| Ray Salomon | M | 61 |
University of California, Berkeley
| 7 anni |
| Pierre Breber | M | 59 |
University of California, Berkeley
| 5 anni |
| Wei-Tek Tsai | M | 64 |
University of California, Berkeley
| 5 anni |
| Richard G. Wallace | M | - |
University of California, Berkeley
| 7 anni |
| Tami S. Smason | F | - |
University of California, Berkeley
| 8 anni |
| Michael J. Estrada | M | - |
University of California, Berkeley
| 3 anni |
| Nat Simons | M | - |
University of California, Berkeley
| 10 anni |
| Adam Rossman | M | 57 |
University of California, Berkeley
| 6 anni |
| Fabio Ignazio Romeo | M | 68 |
University of California, Berkeley
| 4 anni |
| Bahram Nour-Omid | M | - |
University of California, Berkeley
| 4 anni |
| Fu Chieh Hsu | M | - |
University of California, Berkeley
| 3 anni |
| Thomas E. Bell | M | 75 |
University of California, Berkeley
| 4 anni |
| Andreas C. Cangellaris | M | - |
University of California, Berkeley
| 3 anni |
| Jaideep Srivastava | M | - |
University of California, Berkeley
| 4 anni |
| Sosale Shankara Sastry | M | 68 |
University of California, Berkeley
| 3 anni |
| Mark Schena | M | 61 |
The University of California, San Francisco
University of California, Berkeley
| 8 anni |
| Gregory M. Heywood | M | 59 |
University of California, Berkeley
| 12 anni |
| Thomas E. Tighe | M | - |
University of California, Berkeley
| 7 anni |
| Steve Tighe | M | - |
University of California, Berkeley
| 5 anni |
| Michael Cima | M | 64 |
University of California, Berkeley
| 8 anni |
| Lisa Suennen | F | 58 |
University of California, Berkeley
| 5 anni |
| Weijian Shan | M | 70 |
University of California, Berkeley
| 4 anni |
| David Choi | M | - |
University of California, Berkeley
| 5 anni |
| Eric Stonestrom | M | 62 |
University of California, Berkeley
| 6 anni |
| Tony Yao | M | 51 | - | |
| Fabio Romeo | M | - |
University of California, Berkeley
| 4 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 61 | 61.00% |
| Regno Unito | 39 | 39.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- David Kirn
- Contatti personali
